AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors

      Background: In the tumor microenvironment (TME), the endonucleotidase CD73 catalyzes the final step in ATP hydrolysis, generating adenosine (ADO) from adenosine monophosphate (AMP). Extracellular ADO suppresses immune function through activation of A2aR and A2bR receptors expressed on a variety of immune cells. Inhibition of CD73 eliminates a major, non-redundant, pathway of ADO production in the TME, thereby limiting immune suppression. Here we describe the ability of AB680, a small molecule CD73 inhibitor, to potentiate the activity of immune checkpoint inhibitors (ICI) in immune function assays.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect